Skip to content

Rgls stocktwits

Rgls stocktwits

regulus therapeutics inc (rgls): * regulus therapeutics reports first quarter 2020 financial results and recent updates.* q1 loss per share $0.25. * q1 revenue $100,000. * q1 revenue estimate $3.3 million -- refinitiv ibes dat TOGETHER WE… believe that microRNA therapeutics will become a major new class of drugs. We are focused on harnessing their power to target multiple pathways of disease. Find the latest Palatin Technologies, Inc. (PTN) stock quote, history, news and other vital information to help you with your stock trading and investing. At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. Real-time trade and investing ideas on Regulus Therapeutics Inc. RGLS from the largest community of traders and investors. Real-time trade and investing ideas on Virtu Financial VIRT from the largest community of traders and investors.

Dec 16, 2019

Regulus Therapeutics Inc (NASDAQ:RGLS) released its quarterly earnings data on Thursday, May, 14th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.12) by $0.13. The biopharmaceutical company earned $6 million during the quarter, compared to the consensus Real-time trade and investing ideas on ReShape Life Sciences RSLS from the largest community of traders and investors. Guardion Health Sciences Inc, GHSI 0.48 0.02 (3.10%). NASDAQ Updated Jun 8, 2020 11:58 PM Remark Media. MARK 2.60 0.02 (0.76%). NASDAQ Updated Jun 9, 2020 8:01 AM

RGLS - Regulus Therapeutics Inc Stock quote - CNNMoney.com

Featured Post From StockTwits About RGLS $RGLS Upcoming catalysts 1- Delisting - needs to get over 1.00 2- Results for Phase 1 -ADPKD due May/June $RGLS Stock Technical Analysis | Regulus | SwingTradeBot.com RGLS on StockCharts.com Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat various diseases in the United States. The company utilizes its microRNA product platform to develop anti-miRs, a chemically modified single-stranded oligonucleotides.

Get Regulus Therapeutics Inc (RGLS:NASDAQ) real-time stock quotes, news and financial information from CNBC.

RGLS Institutional Ownership - Regulus Therapeutics Inc. Stock Regulus Therapeutics Inc. (US:RGLS) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held) more than 5% of the RGLS: Regulus Therapeutics Inc - Brokerage Recommendations ... RGLS: Regulus Therapeutics Inc broker recommendations. Get the latest broker recommendations from Zacks Investment Research. Regulus Therapeutics Inc. (RGLS): from StockTwitts: Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 5/19/2020 1:51:15 PM Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/18/2020 4:29:00 PM Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/18/2020 4:28:09 PM Quarterly Report (10-q) Edgar (US Regulatory) - 5/14/2020 4:38:29 PM Current Report Filing (8-k) Edgar (US Regulatory) - 5

NewsSee all news. 14 May 2020 Regulus Therapeutics Reports First Quarter 2020 Financial Results and Recent Updates. LA JOLLA, Calif., May 14, 2020 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the

Regulus Therapeutics Inc. RGLS 0.86 0.03 (3.34%). NASDAQ Updated Jun 8, 2020 11:59 PM

Apex Business WordPress Theme | Designed by Crafthemes